ALK and neoplasm: This poses the question of whether the cutoff values for patient enrollment have been chosen sufficiently [17,21,22] or whether MET overexpression determined by IHC may have a low predictive value for MET activation and ET tumor dependency [23] in contrast to, for example, ALK overexpression in ALK fusion-positive NSCLCs [20].